Literature DB >> 27572855

International Pediatric MS Study Group Global Members Symposium report.

Evangeline Wassmer1, Tanuja Chitnis2, Daniela Pohl2, Maria Pia Amato2, Brenda Banwell2, Angelo Ghezzi2, Rogier Q Hintzen2, Lauren B Krupp2, Naila Makhani2, Kevin Rostásy2, Marc Tardieu2, Silvia Tenembaum2, Amy Waldman2, Emmanuelle Waubant2, Andrew J Kornberg2.   

Abstract

The International Pediatric Multiple Sclerosis Study Group held its inaugural educational program, "The World of Pediatric MS: A Global Update," in September 2014 to discuss advances and challenges in the diagnosis and management of pediatric multiple sclerosis (MS) and other neuroinflammatory CNS disorders. Highlights included a discussion on the revised diagnostic criteria, which enable the differentiation of MS, acute disseminated encephalomyelitis, neuromyelitis optica, and other neuroinflammatory disorders. While these criteria currently identify clinical and MRI features for a particular diagnosis, advances in biomarkers may prove to be useful in the future. An update was also provided on environmental factors associated with pediatric MS risk and possibly outcomes, notably vitamin D deficiency. However, optimal vitamin D intake and its role in altering MS course in children have yet to be established. Regarding MS outcomes, our understanding of the cognitive consequences of early-onset MS has grown. However, further work is needed to define the course of cognitive function and its long-term outcome in diverse patient samples and to develop strategies for effective cognitive rehabilitation specifically tailored to children and adolescents. Finally, treatment strategies were discussed, including a need to consider additional drug treatment options and paradigms (escalation vs induction), although treatment should be tailored to the individual child. Of critical importance, clinical trials of newer MS agents in children are required. Although our understanding of childhood MS has improved, further research is needed to have a positive impact for children and their families.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Year:  2016        PMID: 27572855     DOI: 10.1212/WNL.0000000000002880

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report.

Authors:  Marco Capobianco; Antonio Bertolotto; Simona Malucchi
Journal:  Neurol Sci       Date:  2021-03-12       Impact factor: 3.307

2.  First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center.

Authors:  Charalampos Skarlis; Nikolaos Markoglou; Maria Gontika; Anastasia Bougea; Serafeim Katsavos; Artemios Artemiadis; George Chrousos; Marinos Dalakas; Leonidas Stefanis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2022-10-05       Impact factor: 3.830

Review 3.  Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.

Authors:  Gabrielle Macaron; Jenny Feng; Manikum Moodley; Mary Rensel
Journal:  Curr Treat Options Neurol       Date:  2019-09-27       Impact factor: 3.972

Review 4.  Understanding Childhood Neuroimmune Diseases of the Central Nervous System.

Authors:  Sara Matricardi; Giovanni Farello; Salvatore Savasta; Alberto Verrotti
Journal:  Front Pediatr       Date:  2019-12-19       Impact factor: 3.418

5.  Management of pediatric post-infectious neurological syndromes.

Authors:  Elena Bozzola; Giulia Spina; Massimiliano Valeriani; Laura Papetti; Fabiana Ursitti; Rino Agostiniani; Cristina Mascolo; Margherita Ruggiero; Chiara Di Camillo; Anna Quondamcarlo; Luigi Matera; Davide Vecchio; Luigi Memo; Alberto Villani
Journal:  Ital J Pediatr       Date:  2021-01-25       Impact factor: 2.638

6.  Utilization and Treatment Patterns of Disease-Modifying Therapy in Pediatric Patients with Multiple Sclerosis in the United States.

Authors:  Benjamin Greenberg; Scott Kolodny; Mengru Wang; Chinmay Deshpande
Journal:  Int J MS Care       Date:  2020-06-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.